Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Villacampa G, Llop-Guevara A, Filmann N, Herencia A, Fasching PA, Karn T, Marmé F, Klare P, Müller V, Stefek A, Schem C, Uleer C, Fehm T, Doering G, Stickeler E, van Mackelenbergh M, Felder B, Nekljudova V, Balmaña J, Denkert C, Loibl S, Serra V. Villacampa G, et al. Among authors: uleer c. Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148. Online ahead of print. Clin Cancer Res. 2024. PMID: 39786436
Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.
Engel J, Wieder V, Bauer M, Kaufhold S, Stückrath K, Wilke J, Hanf V, Uleer C, Lantzsch T, Peschel S, John J, Pöhler M, Weigert E, Bürrig KF, Buchmann J, Santos P, Kantelhardt EJ, Thomssen C, Vetter M. Engel J, et al. Among authors: uleer c. Breast Cancer Res Treat. 2024 Nov 20. doi: 10.1007/s10549-024-07520-6. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39565513 No abstract available.
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
Martín M, Stecklein SR, Gluz O, Villacampa G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F, Álvarez EL, Echavarría I, Conte B, Kuemmel S, Bueno-Muiño C, Jerez Y, Kates R, Cebollero M, Kolberg-Liedtke C, Bueno O, García-Saenz JÁ, Moreno F, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstleins R, Graeser M, Zu Eulenburg C, Kreipe HH, Gómez H, Massarrah T, Herrero B, Paré L, Bohn U, López-Tarruella S, Vivancos A, Sanfeliu E, Parker JS, Perou CM, Villagrasa P, Prat A, Sharma P, Harbeck N. Martín M, et al. Among authors: uleer c. Ann Oncol. 2024 Oct 16:S0923-7534(24)04061-4. doi: 10.1016/j.annonc.2024.10.012. Online ahead of print. Ann Oncol. 2024. PMID: 39419289 Free article.
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.
Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, Hartkopf AD, Decker T, Uleer C, Stoetzer OJ, Foerster F, Schmidt M, Mundhenke C, Steindorf K, Tesch H, Jackisch C, Fischer T, Hanson S, Kreuzeder J, Guderian G, Fasching PA, Bloch W. Zimmer P, et al. Among authors: uleer c. BMC Med. 2024 Oct 8;22(1):442. doi: 10.1186/s12916-024-03671-x. BMC Med. 2024. PMID: 39379960 Free PMC article.
Prognostic and predictive impact of NOTCH1 in early breast cancer.
Engel J, Wieder V, Bauer M, Kaufhold S, Stückrath K, Wilke J, Hanf V, Uleer C, Lantzsch T, Peschel S, John J, Pöhler M, Weigert E, Bürrig KF, Buchmann J, Santos P, Kantelhardt EJ, Thomssen C, Vetter M. Engel J, et al. Among authors: uleer c. Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07444-1. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39153127
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Fasching PA, Hack CC, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Kellner S, Hofmann NM, Böhm S, Almstedt K, Lück HJ, Schmatloch S, Kalder M, Uleer C, Jurhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Hein A, Fehm TN, Häberle L. Fasching PA, et al. Among authors: uleer c. Eur J Cancer. 2024 Sep;209:114239. doi: 10.1016/j.ejca.2024.114239. Epub 2024 Jul 21. Eur J Cancer. 2024. PMID: 39059184 Free article.
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J; SweBCG, ABCSG and GBG. Matikas A, et al. J Clin Oncol. 2024 Sep 10;42(26):3077-3082. doi: 10.1200/JCO.24.00178. Epub 2024 Jul 17. J Clin Oncol. 2024. PMID: 39018515 Free PMC article. Clinical Trial.
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Nabieva N, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, Fasching PA. Hack CC, et al. Among authors: uleer c. Geburtshilfe Frauenheilkd. 2024 Apr 30;84(2):e10. doi: 10.1055/a-2314-3693. eCollection 2024 Feb. Geburtshilfe Frauenheilkd. 2024. PMID: 38690326 Free PMC article.
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: uleer c. Int J Cancer. 2024 Jul 1;155(1):128-138. doi: 10.1002/ijc.34912. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447007
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, Fasching PA. Hack CC, et al. Among authors: uleer c. Geburtshilfe Frauenheilkd. 2024 Feb 8;84(2):185-195. doi: 10.1055/a-2238-3153. eCollection 2024 Feb. Geburtshilfe Frauenheilkd. 2024. PMID: 38344045 Free PMC article.
51 results